Turkish Compliance and Adaptation of EULAR 2013 Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: Expert Opinion of TLAR

ATAMAN, ŞEBNEM; Surmeli, Zuhre; Sunar, İSMİHAN; Ozdemirel, Erhan; AKINCI, AYŞEN; Bodur, Hatice; AKGÜL, ÖZGÜR; ALTAN İNCEOĞLU, LALE; ALTAY, ZÜHAL; Ayhan, Figen; BİRTANE, MURAT; Soy Bugdayci, Derya; ÇAPKIN, ERHAN; Cerrahoglu, Lale; DURUÖZ, MEHMET; Gunaydin, Rezzan; GÜNENDİ, ZAFER; GÜRER, GÜLCAN; Bal, Ajda; KAÇAR, CAHİT; Kaptanoglu, Ece; Kaya, Taciser; Kocabas, Hilal; Kotevoglu, Nurdan; Nas, Kemal; Rezvani, Aylin; Sen, Nesrin; ŞENDUR, ÖMER; Yalcin, Peyman

doi:10.5606/archrheumatol.2015.5654

Turkish Compliance and Adaptation of EULAR 2013 Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: Expert Opinion of TLAR

Copy For Citation

ATAMAN Ş., Surmeli Z. S., Sunar İ., Ozdemirel E., AKINCI A., Bodur H., ...More

ARCHIVES OF RHEUMATOLOGY, vol.30, no.4, pp.271-284, 2015 (SCI-Expanded)

Publication Type: Article / Article
Volume: 30 Issue: 4
Publication Date: 2015
Doi Number: 10.5606/archrheumatol.2015.5654
Journal Name: ARCHIVES OF RHEUMATOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
Page Numbers: pp.271-284
Keywords: Biologic disease modifying anti-rheumatic drugs, rheumatoid arthritis, synthetic disease modifying anti-rheumatic drugs, treatment recommendations, ADALIMUMAB PLUS METHOTREXATE, INHIBITOR TOFACITINIB CP-690,550, NECROSIS-FACTOR INHIBITORS, DOUBLE-BLIND, INADEQUATE RESPONSE, STRATEGY TRIAL, JAK INHIBITOR, TOCILIZUMAB MONOTHERAPY, ANKYLOSING-SPONDYLITIS, COMBINATION ETANERCEPT
Ankara University Affiliated: Yes

Abstract

Objectives: This study aims to report Turkish League Against Rheumatism's assessment on the compliance of European League Against Rheumatism 2013 treatment recommendations for rheumatoid arthritis with practices in Turkish rheumatology clinics and adaptations for Turkey.